Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Lilly

Status and phase: Completed; Phase 1

Conditions: Neoplasms

Treatments: Drug: Cetuximab + Erlotinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00207077

CA225-101

Details and patient eligibility

About

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

Enrollment: 33 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Measurable disease
• Life expectancy of at least 3 months
• Must have at least one prior chemotherapy containing a platinum

Exclusion criteria

• Known or documented brain metastases
• Prior cetuximab therapy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

33 participants in 1 patient group

A

Experimental group

Treatment:

Drug: Cetuximab + Erlotinib